Key result
Higher total homocysteine linked to ~2.3-fold higher non-valvular AF risk in overweight and obese adults.
Why the study?
The causal role of homocysteine in atrial fibrillation is unclear.
Does elevated homocysteine and MTHFR 677C>T polymorphism increase the risk of non-valvular atrial fibrillation in overweight/obese patients?
Case-Control (n=359)
Yes
Does elevated homocysteine and MTHFR 677C>T polymorphism increase the risk of non-valvular atrial fibrillation in overweight/obese patients?
Relative Risk: 2.333 (95% CI 1.063–5.12)
This study provides evidence supporting a causal role for elevated homocysteine in the development of non-valvular atrial fibrillation among overweight and obese patients.
Supports homocysteine as a potential causal factor for NVAF in obese adults; leaves open whether lowering levels reduces incidence.
Background/Objectives: The causal role of homocysteine (tHcy) in atrial fibrillation (AF) is unclear. To (re)explore the causal effect of tHcy in non-valvular AF (NVAF). Methods: In a case–control study in overweight/obese adults, cases were patients with NVAF and controls were their peers without AF. They were assessed for clinical, laboratory, and echocardiographic particulars and were genotyped for MTHFR 677C>T (rs1801133), PITX2 C>T (rs2200733), and KCNE1 112A>G (rs1805127) polymorphisms. We employed a conventional case–control, mediation analysis, and one-sample Mendelian randomization (MR) analyses to evaluate forward and reverse tHcy-NVAF associations. Results: We enrolled 180 cases and 179 controls. With an extensive confounder control (i) the MTHFR 677C>T variant allele associated with higher tHcy; (ii) PITX2 C>T variant allele associated with NVAF while KCNE1 112A>G did not; (iii) MTHFR variant associated with NVAF indirectly, through tHcy assuming wild type but not variant genotype (exposure–mediator interaction); (iv) considering all subjects, tHcy associated with NVAF through the effect on renal function and NT-proBNP levels (no exposure–mediator interaction); (v) considering MTHFR wild-type subjects (n = 160), tHcy “directly” strongly associated with NVAF, and considering variant carriers (n = 199), it indirectly associated with NVAF and directly tended to associate with a lower probability of NVAF; (vi) in MR analysis (MTHFR SNP instrument), tHcy associated with NVAF; and vii) mediation and MR analyses [PITX2 SNP (exposure/instrument)—NVAF, (mediator/exposure)—tHcy outcome] excluded the reverse tHcy-NVAF association. Conclusions: Data strongly support the causal role of tHcy in NVAF in overweight/obese patients and suggest that the effect might be modified by the MTHFR 677C>T variant allele.
No takes yet. Share an insight, caveat, or question.
Levicki et al. (2025) conducted a case-control in Non-valvular atrial fibrillation (n=359). Total homocysteine (tHcy) vs. Lower total homocysteine levels / Unexposed controls was evaluated on Non-valvular atrial fibrillation (forward tHcy-NVAF association in Mendelian randomization) (RR 2.333, 95% CI 1.063-5.120). Higher plasma total homocysteine was associated with an increased risk of non-valvular atrial fibrillation (RR 2.333) in overweight and obese adults based on Mendelian randomization analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: